Physician profile
Nanditha Krishnamsetty
NPI 1174582746
$4,603.12
in general payments reported to CMS, 2019-2025
18 companies · $612 in 2025
The $612 reported for 2025 was more than what 79% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $237 · 2021: $508 · 2022: $867 · 2023: $1,043 · 2024: $795 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,238 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,237.97 |
| Education | $211.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,514.86 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $696.53 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $645.25 | 2022-2025 | Caplyta |
| Lundbeck LLC | $298.37 | 2019-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $251.85 | 2019-2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $229.98 | 2019-2022 | |
| Allergan, INC. | $214.89 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $202.91 | 2022-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $134.27 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $117.76 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $113.63 | 2019-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $51.02 | 2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $37.38 | 2019-2020 | |
| Axsome Therapeutics, INC. | $32.09 | 2023-2025 | Auvelity |
| Tempus Ai, INC | $22.72 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $15.91 | 2025 | Nuplazid |
| Daiichi Sankyo INC. | $11.99 | 2019 | |
| Bausch Health US, LLC | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nanditha Krishnamsetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.